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Aspergillus is a genus of fungi commonly found in all environments. Remarkably, only a few species cause 
disease and equally remarkably, those same species cause multiple hseases. In the lung, exposure to the fungus, 
the immunological status of the individual and the condition of the lung determine the pattern of Asease. In 
asthmatic patients and those with cystic fibrosis, allergic bronchopulmonary aspergillosis (ABPA) is a 
complication that reduces pulmonary function and, in asthmatics, is substantially improved by itraconazole 
therapy. Patients with pre-existing lung cavities develop aspergillomas (fungal masses inside the cavity). 
Aspergdlomas carry a 40% 5 years survival, and it not clear whether antifungal therapy is helpful. Similar in 
presentation to aspergdloma is chronic necrotizing pulmonary aspergdlosis (CNPA). Development of new or 
expansion of existing pulmonary cavities with surroundmg paracavitary shadowing is the hallmark of CNPA 
These two entities are probably a continuum of the same pathologcal process. Patients with CNPA respond to 
systemic antifungal therapy, but t h s  may need to be lifelong. Surgery is appropriate for isolated aspergdomas, 
but not pleural or multicavity lesions. Aspergillus empyema is a complication of aspergilloma and CNPA, or 
surgery for these diseases and is slow to respond to treatment. 
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INTRODUCTION 
Aspergdlosis is the name given to all diseases caused by the 
fungus in the genus Aspergillus and includes allergic, superficial, 
saprophytic and invasive disease. Although over 150 species of 
Aspergillus are described only a few cause disease with any 
regularity; A.  fumigatus, A.  jlavus, A.  teweus and A.  niger group 
species. The pathogenic Aspergilli are found the world over. 
Soil isolation rates increase towards the equator. Aspergilli are 
common saprophytes in the environment, especially in 
composting facilities. Most aerobiology studies have been 
done in Europe. Most do not show a seasonal variation in 
airborne Aspergillus counts. However, some studies have 
shown an increase in the winter in temperate b a t e s  in the 
Northern Hemisphere. The Aspergilli comprise from 0.1% to 
22% of the total air flora outside and, if speciated, A .  fumigatw 
comprises from 4 to 41% of the total of Aspergilli. The usual 
concentration of conidia in outside air is 2-30 conidia/m3 air 
but can rise to as high as 68 x 106/m3 inside a barn following 
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hay or straw disturbance. In hospitals conima concentrations in 
air also vary typically from 1.0 to 2000/m3 with much 
variation in the same site. Inside human dwellings Aspergilli 
may be found in high concentrations in potted plants (50 
conidia/g soil), damp cellars, dusty crawl spaces and condi- 
ments, especially pepper (lo6 conidia/g in one study) and 
ground spices. 
ABPA 
Wheezing in patients exposed to Aspergillus was recognized in 
the late 1800 s, but was ill-understood. First reported in three 
patients in 1952 from the London Chest Hospital [l], allergic 
bronchopulmonary aspergdosis (ABPA) is an extreme variety 
of continuing local allergy to Aspergillus. ABPA complicates 
asthma and cystic fibrosis (CF). Patients either develop 
exacerbations of asthma and/or CF, but are commonly are 
'difficult-to-control' patients, in the pulmonary sense. Char- 
acteristic presentations include new pulmonary shadows which 
resolve with steroids, coughing up plugs of material, and after 
positive Aspergillus precipitins or an extremely elevated IgE is 
discovered. The diagnosis is made by a combination of criteria, 
of which episodic wheezing (asthma), transient pulmonary 
shadows, elevated serum total IgE and Aspergillus specific IgE, 
positive Aspergillus precipitins and central bronchiectasis are the 
most important. Central bronchiectasis is not a useful 
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diagnostic criterion in CF, as it is universally present. Some 
patients, especially those with long-standing disease, have 
barely detectable Aspergillus precipitins. Other criteria that 
have been used include peripheral eosinophilia and a positive 
immediate skin test to Aspergillus. The first of these is usually 
artificially low in those on steroids, and the second usually 
correlates with the serum Aspergillus specific IgE. 
The serologcal response to Aspergillus infection has been well 
characterized in allergic bronchopulmonary aspergdlosis and 
aspergdloma. The earliest means of detecting Aspergillus anti- 
body was immunodifision but this methodology is not very 
sensitive although it is generally highly reproducible [2,3]. 
Concentration of serum improves sensitivity. Radioimmunoas- 
say (RIA) and ELISA methods have also been developed and are 
routine in some laboratories [2]. RIA and ELISA test results 
vary substantially with the antigens used. There are other 
methods in use including latex agglutination and complement 
fixation. This subject has been reviewed in detail [2,3]. 
Commercially available tests have also been compared [4]. 
AJ3PA can be classified into five stages. These are acute 
remission, exacerbation, corticosteroid dependent, asthma and 
fibrotic. Patients may present in any stage, although it is a 
difficult diagnosis to make with confidence in the fibrotic 
stage. The staging system has less meaning in cystic fibrosis 
because of the progressive deterioration in respiratory status. 
Patients in remission whose respiratory status is good with 
well-controlled asthma or CF require no therapy. Acute 
exacerbations are best treated with systemic corticosteroid 
therapy, usually a daily dose of 40-60 mg prednisolone for 7- 
10 days. Response to corticosteroid therapy can be gauged 
clinically and radiologically; wheezing and breathlessness should 
improve, and radiological idtrates should clear. In patients with 
fkequent exacerbations, inhaled corticosteroids are useful in 
reducing the 6-equency of attacks. Probably this also lowers the 
risk of fibrosis in later years, which is thought to be frequent 
otherwise. Many of these patients, however, require continuous 
systemic corticosteroid therapy to sustain remission. 
Given the natural history of the disease, which is to wax and 
wane, convincing evidence of benefit requires a controlled 
study. For steroid-dependant patients a number of different 
antihngal strateges have been tried. Oral ketoconazole and 
inhaled natamycin are ineffective. Itraconazole 200-400 mg 
per day showed benefit in several open studies [5,6]. Recently 
a controlled trial of oral itraconazole vs. placebo was 
completed and there was a clear benefit of itraconazole over 
placebo in patients who were corticosteroid dependent PI. 
Very few patients with CF have been studied. However, 
itraconazole treatment is associated with lower steroid usage 
and fewer acute ABPA episodes [S] Endpoints for studies in 
CF patients are problematic. Serum concentrations of 
itraconazole CF patients may be low and measurement of 
serum concentrations may be useful as a guide to appropriate 
dosing. There are no use l l  data available on whether 
corticosteroids and/or antifungal agents slow the progression 
of ABPA to pulmonary fibrosis which generally occurs 
between 5 and 11 years after the diagnosis in the preinhaled 
steroid era. It is likely that they will. 
ASPERGILLOMA A N 0  CHRONIC NECROTIZING PULMONARY 
ASPERGILLOSIS COMPARED 
Aspergdoma is the term given to the colonization of an 
intrathoracic cavity by AspergiNus. A fungus ball is formed 
when spores are deposited in the cavity and germinate on the 
wall, where mycelia and debris attach to form an amorphous 
mass (Figure 1). Occasional cases are the result of other fungi, 
such as the Mucorales or Pseudallescheria boydii but these other 
fungi comprise less than 5% of cases of fungal colonization of 
pulmonary cavities. 
Frequency and underlying factors 
An aspergdoma may form in any pre-existing lung cavity. 
There are many causes of pulmonary cavities, including 
tuberculosis, sarcoidosis, pneumoconiosis, hstoplasmosis, bul- 
lae and others. Some idea of the prevalence of aspergdoma can 
be gained &om a reported review of 60 000 chest radiographs: 
aspergillomata were identified in 0.01%. During an 11-year 
period, 15 patients with aspergdloma were admitted to a 
Veteran’s Administration Hospital, representing 0.02% of 
adnlissions. The frequency is high in patients with cavities 2 
cm or more in diameter. For example, in tuberculosis cavities 
of this size, 15-20% of UK patients developed an aspergilloma 
Figure 1 CT scan of the upper thorax in a patient showing multiple 
cavities and a large irregular aspergilloma in the right upper lobe. Some 
pleural thickening is apparent, as are some paracavitary infiltrates. This 
patient is a poor candidate for surgery. The diagnosis is probably 
chronic necrotizing pulmonary aspergillosis. 
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[9] In another senes in patlents with pulmonary sarcoidosis, 
10 of 19 (53%) pahents w t h  cysuc parenchymal damage from 
sarcoidosis had aspergdomas compared w t h  none of 81 
patlents w t h  noncystic pulmonary sarcoidosis [lo]. 
The incidence of chromc necroazing pulmonary aspergl- 
losis (CNPA) IS not known Most pahents m t h  CPNA, if not 
all, have pnor pulmonary disease [11J A healed tuberculous 
canty, whether the result of typical or atypical mycobactena, 
is common. Somenmes d~snnguishng an aspergdoma and 
CNPA can be difficult, pamcularly If a prevlous chest 
ramograph is not avadable. Other underlying pulmonary 
condiaons include chronic obstructive pulmonarv disease, 
ankylosing spondyks, recurrent pneumothorax, thoracic 
surgery and kyphoscohosis [12]. Corticosteroid therapy may 
be implicated but, if so, tends to lead to a more severe and 
rapid course. Diabetes me&tus, excess d~ohol consumphon 
and chromc h e r  & s e a  are occasional antecedents. In a recent 
report of aspergdlomas in AIDS [13], progression of 
‘aspergdomas’ over ame was seen w t h  conaderable morbid- 
ity and some mortahty. Thus probably reflects mvasion of 
cavity walk by Aspergrllus rather than simple colonizahon of 
Ptzeumocystrs cavihes by Aspergdus and is either CNPA or 
invasive aspergdosis mtochrondnal defects (Pearson and 
MELAS syndromes) have recently been associated with 
invasive aspergdlosis [14,15]. We have also recently descnbed 
mannose bindmg protein deficiency as a probable associatlon 
w t h  CNPA (Crosdale et a / ,  unpubhshed data). 
Clinical presentation 
The symptoniatology of aspergilloma is variable in individual 
patients over time. Most patients are asymptomatic when an 
aspergdoma first forms. The commonest presentation is that of 
hemoptysis, whch initially is usually minor. In association 
with this, most patients have cough and productive sputum. 
About 40% of patients are ‘sensitized’ to Aspergillus and 
develop wheezing, weight loss and malaise with or without 
fever. The patient is typically in the 4th-6th decade of life and 
more men than women are afTected. Hemoptysis may be 
progressive and is frequently severe (> 150 mL blood daily). 
A considerable proportion of patients die dlrectly as a result of 
exsanguinating hemorrhage. 
CNPA presents in three ways. Constitutional symptoms are 
prominent in all patients with weight loss, malaise and fitigue. 
The most common presentation is a chronic productive cough. 
The second common presentation is hemoptysis, which varies 
from severe to trivial. The third is with only constitutional 
symptoms. Dyspnea is a common feature but usually reflects 
underlying lung disease unless CNPA is very distinctive. Chest 
pain is uncommon, but does occur. Features ofbronchiectasis are 
also common and may coexlst. Finger clubbing also occurs. 
Radiology 
Plain radiography of the chest in cases of asperglloma shows a 
number of typical features, including a round solid mass withn 
a cavity separated from the wall of the cavity by a rim of air 
[16]. This rim of air is known as the ‘crescent sign’ (not to be 
confused with the ‘air crescent’ sign in invasive aspergillosis) 
and is virtualry diapostic of an aspergdoma (Figure 1). 
Typically, pleural hckening is also present and this may vary 
from several &metres to 2 cm. Pleural thickening m y  
antedate the appearance of the aspergdoma on chest radio- 
graphs and is therefore a clue to the dagnosis of aspergdoma 
in patients with other pulmonary disease such as sarcoidosis. 
Computed tomognphic (CT) scans are useful in dubious 
cases. However, some pleural thickening is also common 
following pulmonary tuberculosis. The aspergdloma may be 
mobile within the cavity. Mobihty of the mass is most easily 
demonstrated on CT s c ~  by totating the patient. 
Classification of aspergdlomas into simple and complex may 
be therapeutically useful. Simple aspergdlomas have thin- 
walled cysts with little surrounding parenchymal disease. 
Complex aspergdlomas have thick-walled cavities with 
associated parenchymal infiltrates [Figure 1). In such instances, 
the aspergdoma consists of an irregular mass containing air 
spaces. Many, if not all, of these complex aspergillomas are in 
fact CNPA (see below). In addtion, aspergdomas may be 
primarily pulmonary, pleural or bronchal in location. 
All patients with CNPA exhibit radiologcal evidence of a 
cavitary lesion in the lung, usually in one or both upper lobes. 
Initially, infiltrates are ill-defined areas of consolidation or small  
cavities that progressed to form well-defined cavities (Figures 2- 
7). Cavities may be large or small. The cavities often contain an 
aspergdoma, debris or fluid. Over time, these cavities became 
multiple with thickened walls (Figure 8). In those cases where 
cavities pre-existed (i.e. in cases of prior tuberculosis or 
bronchiectasis) , cavity expansion and paracavitary infiltrates 
are characteristic. Such new findings in a patient previously 
diagnosed with CNPA are characteristic of clinical relapse or 
deterioration. Some patients have pleural thickening and ths  
may progress to form a broncho-pleural fistula. 
Serology 
Aspergillus precipitins (IgG antibody) are detectable in over 
95% of patients with aspergdloma. Some have IgM antibodies 
as well. Successful surgical removal of an aspergdoma will 
result in a fall of Aspergillus antibody to (usually) undetectable 
levels over the following few months. The precipitin test may, 
however, be positive in some patients with cavities who do 
not have an overt aspergdoma, and these patients probably 
have CNPA. Most patients with aspergdoma have positive 
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Figure 2 Right upper lobe from a male patient (MS) of 54 years with 
diabetes mellitus and pulmonary Myobacterium avium infection, 
showing small cavitary lesion, October 1995. 
respiratory cultures of Aspergillus, usually A. fumigutus. In a 
retrospective series, 25% of those with pulmonary aspergdo- 
mas, 100% of those with a sinus aspergdoma, and 8% with 
disseminated aspergdosis had calcium oxalate crystals identi- 
fied in tissue [17]. A. niger may be a more prolific producer 
than Afirmigatus. Occasionally renal oxalosis is observed [17]. 
All, or almost all, patients with CNPA have A. fumigutus 
precipitins in blood. The titer of antibodies vanes over time 
and may occasionally be negative at some time in the course of 
CNPA. Elevation of acute phase markes such as C-reactive 
protein, plasma viscosity are a useful clue to the diagnosis, if 
the distinction between CNPA and aspergdoma is difficult to 
draw. Two-thirds of patients have elevated levels of total I@ 
and Aspergillus specific IgE. 
Other diagnostic measures 
Patients with aspergdomas usually grow Aspergillus from 
sputum with ease and multiple variants and genotypes may 
be recovered. 
Sputum cultures may be positive in CNPA and Aspergillus is 
typically the sole pathogen isolated. However positive cultures 
Figure 3 Right upper lobe from patient MS with the formation of a 
circular shadow, partly filled by a mass, June 1997. 
are infrequent and may occur years after the patient first 
presents. Bronchoscopy samples may also be positive by culture. 
Confirmation of the diagnosis can be difticult and the 
characteristic radiological and serological findings are sufficient. 
Histologically hyphae may be found in abnormal cavities 
without invading tissue. Lung resection may be necessary to 
iden+ such hyphae as bronchoscopic and percutaneous biopsies 
have usually been negative histologically. Other findings 
compatible with CNPA include chronic inflammatory reaction, 
with or without nonspechc granuloma fomt ion  without 
hyphae being visualized. In contrast, percutaneous biopsies were 
positive microbiologically on two or three occasions. 
Natural history 
Spontaneous resolution of aspergdomas is recognized to occur 
in 10% of cases within 3 years [9]. However the consequences 
of this type of Aspergillus infection can be dramatic. One report 
focussed on the long-term outcome of 23 patients with 
aspergdoma, five of whom died directly from complications 
of this infection [18]. Many patients with asperflomas are 
elderly and have significant underlying disease, including 
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Figure 4 Right upper lobe from patient MS showing the expansion of 
the shadow, still partially filled with a mass, March 1998. 
Figure 5 Right upper lobe from patient MS with a huge cavity 
containing some debris, with positive Aspergillus precipitins. Needle 
aspiration did not yield Aspergillus, but he responded to itraconazole 
(weight increase, reduced coughing and reduced fatigue), May 2000. 
severe respiratory compromise in addition to the aspergilloma. 
Thus, many patients die with an aspergdoma rather than of it. 
Untreated CNPA runs a slowly progressive course over 
months or usually years. Cavities expand reducing pulmonary 
capacity, local pulmonary fibrosis occurs and eventually the 
patient is left with little functional lung. Sometimes the 
systemic features are more prominent and cachexia, mimick- 
ing carcinoma, is the eventual outcome. Fatal hemoptysis 
occasionally occurs. 
Treatment 
Several therapeutic strategies have been used in treating 
aspergdomas. Systemic antifungal therapy with ketoconazole 
is ineffective' ltraconazole 2oo mg is Of 
s v p t o m t i c  benefit and little radologica benefit [1% work 
&om Japan has shown that the drug does accumulate in the 
hngal ball and cavity [20], but responses are incomplete. 
Repeated instillations of nystatin or amphotericin B into the 
cavity have yielded some benefit in some cases (especially with 
amphotericin B) [21]. Communication between the cavity and 
the airways is usual so the instilled agent usually leaks into the 
Figure 6 CT scan (single cut) of the upper thorax of patient MS 
showing a textbook example of an air crescent so typical of an 
aspergilloma, but without any pleural thickening, which is unusual for 
an aspergilloma, September 1998. 
airways. Repeated instillations are labor intensive and not very 
effective for complex and/or bilateral asperdomas. The more 
Q 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMl, 7 (Suppl. 2). 25-31 
30 Clinical Microbiology and Infection, Volume 7, Supplement 2. 2001 
Figure 7 CT scan (single cut) of the upper thorax of patient MS 
showing marked progression of the lesion over 18 months, with no 
treatment, March 2000. Collectively these images show the evolution 
over 5 years from a very small cavity presumably from the M. avium 
infection, to the development of an aspergilloma, which expanded 
slowly to a huge cavity. He improved with antifungal therapy, although 
the cavity remains large. 
Figure 8 A CT scan of the thorax in a patient with CNPA presenting 
with profound weight loss and coughing on a background of 
emphysema and smoking The scan shows multiple cavities bilaterally, 
with an aspergilloma on the left in one small cavity and much pleural 
thickening He was thought to have carcinoma by Aspergillus 
precipitins and sputum cultures were positive He responded partially 
to itraconazole, but developed ankle edema and did poorly with 
intravenous amphotericin B with renal dysfunction and pulmonary 
decompensatton 
recent use of amphotericin B in gelatin or glycerin that 
solidifies at 37 "C and instilled through a flexible plastic 
catheter have been successful [22-241. Details of how to 
make up this preparation and instill it are described on 
www.aspergillus.man.ac.uk/secure/treatment. It is important 
to ensure that little or none leaks into the airways in patients 
with precarious pulmonary function. 
AU patlents m t h  CNPA require systemc antlfungal 
treatment, although the urgency of t h s  is vanable. Expenence 
m t h  amphotencin B, itraconazole or vonconazole indlcates 
that the condltlon is incurable and either hfelong therapy or 
prolonged penods of therapy are required to prevent 
progression and improve symptoms. Amphotencin B should 
be used systermcally and a dose of 0.5-1 mg/kg per day 
(conventional) or 4-5 mg/kg (hpid based) gwes good results 
after the patlent has completed therapy, pamcularly if 
itraconazole is contlnued subsequently. Itraconazole as 
pnmary therapy is effectlve in about 45% of cases and appears 
stdl to be effectlve suppressive therapy after amphotencin B, 
even if it fals as pnmary therapy. 
Treatment of CNPA is best evaluated by following chn~cal, 
radiologcal, serologcal and mcrobiologcal parameters Use- 
ful parameters of response inciude weight gain and energy 
levels, improved pulmonary symptoms, W n g  inflammatory 
markers and total serum IgE, improvement in paracavitary 
infiltrates and eventually a reduction in cavrty me. Haemop- 
tysis is not a useful guide to response - if severe, embohzahon 
should be considered. Surgml resectlon should be avoided, if 
possible, as h s  is technically dtfficult and Aspergillus empyema 
and/or bronchpleural fistula is a common subsequent problem 
Surgery may be appropnate for patients wth aspergdloma 
and hemoptysis In those patlents wth major hemoptysis and 
simple aspergdomas, surgery offers an 84% five year survival 
compared wlth a 41% survival wlth conservatlve therapy [25] 
More recent senes have substantlally lower mortahty rates, 
particularly if patlents are selected carefully [26,27] Surgcal 
removal of aspergdomas is fraught wlth dlfficulty because of 
the very vascular, adherent pleura and the t e c h c a l  challenge 
Aspergdomas in old tuberculous cavihes fare less well as do 
those requinng pneumonectormes [28] This ofien results in 
the spdlage of cavity contents into the pleura resulting in the 
chest cavity becormng infected m t h  Aspergillus [29] Patlents 
wlth complex aspergdomas (who probably have CNPA) do 
not fare well wlth surgery Surgical removal of pleural 
aspergdomas and thoracoplasty is also prone to many 
comphcations and should be avoided if possible [30]. In 
addltion, many patients have underlymg respiratory insuffi- 
ciency and removal of a lobe of the lung would leave them 
unacceptably breathless 
In those patlents m t h  hemoptysis who are not fit to 
undergo surgery, embohzatlon of bleedlng vessels by a slulled 
interventional radlologst may be appropnate In most 
instances of hemoptysis abnormal and novel vascular connec- 
hons to the systemc circulation are implicated Usually, t h s  is 
the bronchial circulahon but it may be any of the other artenes 
supplying the chest including the internal or external 
mammary artenes Several abnormal vascular connections 
may coexist 
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ASPERGlL LUS E M  PY E M A  
The most common cause of Arpergillus empyema is rupture or 
surgical removal of an aspergdoma or CNPA [31]. Sometimes 
the pleura is directly involved. Symptoms of fever, cough and 
weight loss are typical. A bronchopleural fistula is a common 
additional finding. Aspiration of the pleural cavity yields 
Aspergilhs and biopsy of the pleura or wall of the cavity 
confirms the diagnosis histologically. Drainage of an empyema 
with creation of a deep pleurocutaneous fistula (e.g. an 
Eloesser flap) [32] is typically necessary. Other approaches 
have included using free muscle flaps to fill the pleural space. 
Ths is usually effective but disfiguring. Local irrigation with 
s a h e  and/or sugar paste, oral itraconazole and patience will 
usually allow the cavity to slowly fill in and heal. However this 
can take months or years. If the patient has very significant 
pulmonary dysfunction rendering surgery difficult or impos- 
sible, a combination of systemic antifungal therapy with 
instillation of amphotericin B paste into the pleural cavity is 
the optimal therapeutic approach. As pleural aspergdlosis tends 
to be chronic and indolent many months of therapy are usually 
required and often the disease can only be stabdized with 
improvement of symptoms, without f d  resolution or cure. 
OTHER CHRONIC SYNDROMES 
Other syndromes possibly or probably completely or partly 
attributable to Aspergillus include extrinsic allergic alveolitis, 
exacerbation of asthma without ABPA, bronchocentric 
granulomatosis, some episodes of bronchitis and systemic 
syndromes related to excessive environmental exposure. These 
entities require more research to fully understand their 
relationship to Aspergillus and other fun9 and to understand 
better their pathogenesis and optimum treatment. 
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